SKINVISIBLE, INC.
SKINVISIBLE, INC. (SKVI): 4 pipeline candidates · ~31 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
31.3 months
D/E -1.01 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for SKINVISIBLE, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.1M
Cash
$2K
Quarterly Burn
$822
Runway
31.3 mo
Revenue
$5K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| dermsafe | Approved |
| procort | Approved |
| qrx003 | Phase 1 |
| skinbrella | Approved |
Frequently asked questions
How many drug candidates are in SKINVISIBLE, INC.'s pipeline?
SKINVISIBLE, INC. (SKVI) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SKINVISIBLE, INC.'s lead drug candidate?
SKINVISIBLE, INC.'s most advanced tracked candidate is dermsafe (Approved) for Hand sanitization.
What is SKINVISIBLE, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SKINVISIBLE, INC. has approximately 31.3 months of cash runway.
What is SKINVISIBLE, INC.'s market capitalization?
SKINVISIBLE, INC.'s market capitalization is approximately $1.1M.
Who is the CEO of SKINVISIBLE, INC.?
Mr. Terry H. Howlett is the chief executive officer of SKINVISIBLE, INC. (SKVI).
Get the full picture on SKINVISIBLE, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.